# OnCo record calgb-40603 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/calgb-40603/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "calgb-40603", "NCT00861705" ;
  schema:name "CALGB 40603 (Alliance)"@en ;
  schema:alternateName "CALGB 40603"@en, "Alliance 40603"@en ;
  schema:description "CALGB 40603 showed that adding carboplatin to pre-operative chemotherapy made more triple-negative tumours disappear, but at nearly eight years of follow-up neither carboplatin nor bevacizumab clearly improved survival, in a trial too small to prove that either way."@en ;
  schema:url <https://onco.cc/trials/calgb-40603/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00861705>, <https://doi.org/10.1200/JCO.2014.57.0572>, <https://doi.org/10.1200/JCO.21.01506> ;
  onco:status "mixed" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/> ;
  onco:institutions <https://onco.cc/institutions/nci/>, <https://onco.cc/institutions/alliance-oncology/> ;
  onco:terms <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/efs/> ;
  onco:trials <https://onco.cc/trials/geparsixto/>, <https://onco.cc/trials/brightness/>, <https://onco.cc/trials/keynote-522/> .